Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SIBN 
Si-Bone Inc (SIBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SIBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25
1 Year Target Price $25
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.95% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 677.31M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 9 | Beta 0.81 | 52 Weeks Range 11.70 - 20.05 | Updated Date 09/14/2025 |
52 Weeks Range 11.70 - 20.05 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.83% | Operating Margin (TTM) -14.4% |
Management Effectiveness
Return on Assets (TTM) -7.59% | Return on Equity (TTM) -14.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 568702695 | Price to Sales(TTM) 3.66 |
Enterprise Value 568702695 | Price to Sales(TTM) 3.66 | ||
Enterprise Value to Revenue 3.07 | Enterprise Value to EBITDA -14.15 | Shares Outstanding 43140900 | Shares Floating 39252212 |
Shares Outstanding 43140900 | Shares Floating 39252212 | ||
Percent Insiders 2.98 | Percent Institutions 96.62 |
Upturn AI SWOT
Si-Bone Inc
Company Overview
History and Background
SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California. The company focuses on developing and commercializing minimally invasive surgical (MIS) devices for the treatment of sacroiliac (SI) joint dysfunction. It has evolved from a research and development phase to a commercial entity with a global presence.
Core Business Areas
- Sacroiliac Joint Fusion: SI-BONE's primary business is the iFuse Implant System, a minimally invasive surgical procedure for SI joint fusion.
Leadership and Structure
Laura S. Francis is the Chief Executive Officer. The organizational structure includes departments for sales, marketing, research and development, operations, and finance.
Top Products and Market Share
Key Offerings
- iFuse Implant System: The iFuse Implant System is a minimally invasive surgical option for patients suffering from SI joint pain. Competitors include other SI joint fusion systems from companies like Medtronic and Globus Medical. SI-BONE reports that 80% of SI joint fusion is performed using its iFuse system. Number of patients undergoing Si-Bone procedure is approximately 40,000 annually
Market Dynamics
Industry Overview
The market for SI joint fusion is growing due to increasing awareness of SI joint dysfunction as a cause of lower back pain and the development of minimally invasive surgical techniques.
Positioning
SI-BONE is a leader in the SI joint fusion market, known for its iFuse Implant System and clinical research supporting its efficacy. It holds a significant market share in minimally invasive SI joint fusion.
Total Addressable Market (TAM)
The estimated TAM for SI joint fusion is upwards of $2 billion annually, based on the prevalence of SI joint dysfunction and the potential number of patients who could benefit from the procedure. Si-Bone is positioned to capture a significant portion of this market through its established presence and clinical data.
Upturn SWOT Analysis
Strengths
- First mover advantage in minimally invasive SI joint fusion
- Strong clinical evidence supporting the iFuse Implant System
- Established distribution network
- Focused on a specific niche market
Weaknesses
- Reliance on a single product (iFuse Implant System)
- Reimbursement challenges from insurance providers
- Limited product diversification
- Smaller market capitalization compared to competitors
Opportunities
- Expanding into new geographic markets
- Developing new products for related orthopedic conditions
- Increasing awareness of SI joint dysfunction among healthcare professionals and patients
- Capitalizing on the trend towards minimally invasive surgery
Threats
- Competition from larger orthopedic companies
- Changes in reimbursement policies
- Potential for product liability claims
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- GMED
- NXTC
Competitive Landscape
SI-BONE competes with larger orthopedic companies like Medtronic (MDT) and Globus Medical (GMED) that offer alternative SI joint fusion systems. SI-BONE's advantage lies in its focus on minimally invasive techniques and its strong clinical evidence, while its disadvantages include its smaller size and limited product diversification.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires access to live updated data which I do not have the ability to access.
Future Projections: Future projections require access to live updated data which I do not have the ability to access.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts to raise awareness of SI joint dysfunction, and pursuing new clinical research to support the iFuse Implant System.
Summary
SI-BONE is a key player in the growing SI joint fusion market, primarily through its iFuse Implant System. The company's strengths include a strong clinical record and focused approach, but it faces challenges from larger competitors and reimbursement hurdles. Future success depends on expanding its product line, navigating regulatory challenges, and maintaining its innovative edge in the SI joint market. Revenue growth will be based on increased adoption and penetration of the iFuse product.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Si-Bone Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2018-10-17 | CEO & Director Ms. Laura A. Francis MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 349 | Website https://si-bone.com |
Full time employees 349 | Website https://si-bone.com | ||
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.